New hope for tough prostate cancer: BNT324 takes on chemo
NCT ID NCT07365995
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called BNT324 against standard chemotherapy (docetaxel) in men with metastatic castration-resistant prostate cancer that has progressed after hormone therapy. The goal is to see if BNT324 helps patients live longer without their cancer worsening. About 736 men will participate in this Phase 3 trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BNT324 (also called DB-1311)
What this could lead to
If it works, BNT324 could offer a more effective treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong
This is an early-stage Phase 3 trial, so results are not guaranteed. The new drug may not work better than current chemotherapy and could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Illinois Cancer Specialists
RECRUITINGNiles, Illinois, 60714, United States
-
Maryland Oncology Hematology
RECRUITINGRockville, Maryland, 20850, United States
-
Rocky Mountain Cancer Centers
RECRUITINGAurora, Colorado, 80012, United States
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Texas Oncology - West Texas
RECRUITINGWichita Falls, Texas, 76310, United States
-
Texas Oncology Gulf Coast
RECRUITINGHouston, Texas, 77024, United States
-
Texas Oncology South Austin
RECRUITINGAustin, Texas, 78731, United States
-
Texas Oncology, P.A. - Tyler
RECRUITINGTyler, Texas, 75702, United States
-
Virginia Cancer Specialists PC
RECRUITINGFairfax, Virginia, 22031, United States